Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRM421 in Dry Eye Disease
NCT07078955Phase 2Not yet recruiting
- Sponsor
- BRIM Biotechnology, Inc.
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of BRM421 in dry eye disease (DED), sponsored by BRIM Biotechnology, Inc.. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
BRM421
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07078955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07078955.